# Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

> **NCT03560986** · PHASE3 · TERMINATED · sponsor: **Grünenthal GmbH** · enrollment: 267 (actual)

## Conditions studied

- Complex Regional Pain Syndrome (CRPS)

## Interventions

- **DRUG:** Neridronic acid 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03560986
- **Lead sponsor:** Grünenthal GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-31
- **Primary completion:** 2019-08-01
- **Final completion:** 2019-08-01
- **Target enrollment:** 267 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03560986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03560986, "Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03560986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*